Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the World Health Organization classifying it as a deadly zoonotic virus with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical Holdings Limited is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., is a high-tech enterprise established through a strategic investment with Carbon Cloud Intelligence, focusing on molecular diagnostics and offering comprehensive solutions in research, production, and technical services [1] Group 2: Technological Solutions - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, capable of supporting the entire process from rapid screening to precise tracing [1] - The intelligent fluorescent PCR rapid detection platform utilizes an AI primer design platform, integrating gene retrieval, automated primer design, and multi-dimensional performance evaluation, achieving rapid and accurate detection of high-risk pathogens like Nipah virus [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution covering both "wet experiments and dry analysis," enabling simultaneous detection and differentiation of Nipah virus and other co-existing pathogens [4] Group 3: Strategic Development - The rapid deployment of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant step in Huajian Medical's overall AI healthcare strategy [6] - The company is advancing its acquisition of Chuangye Huikang Technology Co., Ltd., aiming to establish a next-generation public health prevention paradigm that integrates AI early warning, rapid diagnosis, and ecological collaboration [6] - The product launch and strategic articulation demonstrate the company's commitment to the core paradigm of "intelligent capital driving continuous profit from knowledge," enhancing innovation efficiency and commercial value within its ecosystem through technology integration, data collaboration, and capital empowerment [6]
华检医疗(01931.HK)旗下子公司碳华生物已成功研发出针对尼帕病毒的双平台检测解决方案